ALSO NOTED: BMS adds new safety review; FDA's chief attorney departs; Novartis completes Betaseron switch

> Bristol-Myers Squibb has hired the consulting firm Accenture as a drug-safety sidekick. From its Life Sciences Center in Chennai, India, Accenture will gather and analyze worldwide safety data on Bristol-Myers' drugs and drug candidates. Release

> The FDA's lawyer-in-chief Sheldon Bradshaw split for the private sector a few days ago, the agency announced. Release

> Novartis says it's finished transferring manufacturing of its Betaseron multiple sclerosis treatment to Bayer Schering; the companies announced the $200 million deal in March. Report

> Pfizer will discuss its pipeline with investors at the Interscience Conference on Antimicrobial Agents and Chemotherapy meeting September 18. Report

> Pharma services firm McKesson has alerted thousands of patients that their private info--including Social Security numbers, prescriptions, and dates of birth--was stored on two computers stolen from a company office. The company helps pharmaceutical firms set up need-based assistance programs. Report

And Finally... When drugs fail to save limbs, use maggots. Approved as "medical devices" by the FDA since 2004, the fly larvae are growing in popularity as a last-resort treatment before amputation; it's successful in almost half of patients. Article

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.